Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

Abstract Background The primary aim of this study was to evaluate the safety of a novel dendritic cell (DC) vaccine pulsed with survivin and MUC1, silenced with suppressor of cytokine signaling 1 (SOCS1), and immune stimulated with flagellin for patients with stage I to IIIA non-small cell lung canc...

Full description

Bibliographic Details
Main Authors: Chunlei Ge, Ruilei Li, Haifeng Song, Tao Geng, Jinyan Yang, Qinghua Tan, Linfeng Song, Ying Wang, Yuanbo Xue, Zhen Li, Suwei Dong, Zhiwei Zhang, Na Zhang, Jiyin Guo, Lin Hua, Siyi Chen, Xin Song
Format: Article
Language:English
Published: BMC 2017-12-01
Series:BMC Cancer
Subjects:
Modified-DCvaccine
Non-small cell lung cancer (NSCLC)
Phase I clinical trial
Online Access:http://link.springer.com/article/10.1186/s12885-017-3859-3

Internet

http://link.springer.com/article/10.1186/s12885-017-3859-3

Similar Items